NCT03916081 - Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions

Atopic Dermatitis

Interventions

DRUG

Roflumilast Cream 0.05%

Roflumilast 0.05% cream for topical application

DRUG

Roflumilast Cream 0.15%

Roflumilast 0.15% cream for topical application

DRUG

Vehicle Cream

Inactive vehicle cream matched to roflumilast cream for topical application.

Trial Locations (20)

15213

Arcutis Clinical Site 23, Pittsburgh

23224

Arcutis Clinical Site 21, Richmond

27262

Arcutis Clinical Site 02, High Point

32771

Arcutis Clinical Site 17, Sanford

33016

Arcutis Clinical Site 19, Hialeah

33174

Arcutis Clinical Site 18, Miami

37130

Arcutis Clinical Site 20, Murfreesboro

43209

Arcutis Clinical Site 08, Bexley

46168

Arcutis Clinical Site 13, Plainfield

46250

Arcutis Clinical Site 12, Indianapolis

55432

Arcutis Clinical Site 03, Fridley

70006

Arcutis Clinical Site 15, Metairie

77845

Arcutis Clinical Site 09, College Station

78213

Arcutis Clinical Site 04, San Antonio

83713

Arcutis Clinical Site 16, Boise

85254

Arcutis Clinical Site 25, Scottsdale

92123

Arcutis Clinical Site 01, San Diego

K9A 4J9

Arcutis Clinical Site 14, Cobourg

L4B 1A5

Arcutis Clinical Site 10, Richmond Hill

H2K 4L5

Arcutis Clinical Site 06, Montreal